We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-0.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.89B
AUM Growth
-$643M
Cap. Flow
-$392M
Cap. Flow %
-5.69%
Top 10 Hldgs %
36.47%
Holding
178
New
7
Increased
49
Reduced
68
Closed
19

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$49.8M
2
ALGN icon
Align Technology
ALGN
+$27.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.9M
4
VEEV icon
Veeva Systems
VEEV
+$13.1M
5
LEGN icon
Legend Biotech
LEGN
+$7.46M

Top Sells

Rank Stock Value
1
MYOV
Myovant Sciences Ltd.
MYOV
+$159M
2
CI icon
Cigna
CI
+$30.6M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$27.6M
4
ELV icon
Elevance Health
ELV
+$26.9M
5
DXCM icon
DexCom
DXCM
+$26.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.07%
2 Industrials 0.84%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCYC
126
Bicycle Therapeutics
BCYC
$290M
$1.13M 0.02%
53,200
-17,000
-24% -$426K
GDX icon
127
VanEck Gold Miners ETF
GDX
$21.6B
$1.07M 0.02%
33,000
+14,600
+79% +$442K
ETNB
128
DELISTED
89bio
ETNB
$1.02M 0.01%
+67,000
New +$874K
AKRO
129
DELISTED
Akero Therapeutics
AKRO
$999K 0.01%
26,100
-16,550
-39% -$738K
MCK icon
130
McKesson
MCK
$97.3B
$975K 0.01%
2,739
-181
-6% -$65.4K
VTYX
131
DELISTED
Ventyx Biosciences
VTYX
$854K 0.01%
+25,500
New +$992K
MRUS
132
DELISTED
Merus
MRUS
$841K 0.01%
45,700
– –
CAH icon
133
Cardinal Health
CAH
$52.9B
$800K 0.01%
10,600
– –
MRK icon
134
Merck
MRK
$307B
$753K 0.01%
7,075
+324
+5% +$35K
SPY icon
135
State Street SPDR S&P 500 ETF Trust
SPY
$781B
$737K 0.01%
1,800
– –
DNLI icon
136
Denali Therapeutics
DNLI
$3.63B
$714K 0.01%
31,000
– –
XNCR icon
137
Xencor
XNCR
$1.39B
$708K 0.01%
25,400
– –
RCKT icon
138
Rocket Pharmaceuticals
RCKT
$375M
$627K 0.01%
36,600
– –
GOOG icon
139
Alphabet (Google) Class C
GOOG
$4.29T
$624K 0.01%
6,000
– –
INBX
140
DELISTED
Inhibrx, Inc. Common Stock
INBX
$560K 0.01%
29,700
– –
ARWR icon
141
Arrowhead Research
ARWR
$10.1B
$541K 0.01%
21,300
– –
SEER icon
142
Seer Inc
SEER
$112M
$525K 0.01%
136,133
– –
XOP icon
143
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.34B
$498K 0.01%
3,900
– –
ZTS icon
144
Zoetis
ZTS
$31.9B
$229K ﹤0.01%
+1,373
New +$225K
MCHI icon
145
iShares MSCI China ETF
MCHI
$6.12B
$205K ﹤0.01%
4,100
– –
GDXJ icon
146
VanEck Junior Gold Miners ETF
GDXJ
$6.62B
$198K ﹤0.01%
5,000
– –
OPT
147
DELISTED
Opthea Limited American Depositary Shares
OPT
$186K ﹤0.01%
47,000
– –
IPGP icon
148
IPG Photonics
IPGP
$4.16B
$129K ﹤0.01%
1,050
– –
DGX icon
149
Quest Diagnostics
DGX
$23B
$123K ﹤0.01%
+870
New +$124K
BMY icon
150
Bristol-Myers Squibb
BMY
$123B
$104K ﹤0.01%
1,496
-48,759
-97% -$3.44M
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2023 Portfolio in Review

As of Q1 2023, Bellevue Group held 178 positions worth $6.89B, down 8.5% from $7.53B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group withdrew a net $392M in Q1 2023, closing 19 positions and reducing 68 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $159M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Verona Pharma worth $5.27M.

  • Bellevue Group's largest Q1 2023 buy was Verona Pharma: 262,683 shares worth $5.27M.
  • Bellevue Group added most to Medtronic in Q1 2023, an estimated $49.8M increase.
  • Bellevue Group's biggest Q1 2023 reduction was Cigna, cutting an estimated $30.6M.
  • Bellevue Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $159M.
  • Bellevue Group's ten largest holdings make up 36% of its $6.89B portfolio in Q1 2023.
  • Bellevue Group opened 7 new positions and closed 19 in Q1 2023.
  • Bellevue Group's portfolio value fell 8.5% quarter-over-quarter to $6.89B.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.